ZuraBio

At Zura Bio, we are committed to developing novel medicines for severe immune disorders

[ZuraBio @ZuraBioLimited]

Tibulizumab, a potential first-in-class bispecific antibody targeting BAFF and IL-17, continues to advance across our clinical programs.

We’re excited to share that Zura Bio has completed enrollment in our Phase 2 TibuSHIELD trial in hidradenitis suppurativa (#HS), with our Phase 2 TibuSURE trial in systemic sclerosis (#SSc) nearing full enrollment. Building on this momentum, we plan to initiate a third Phase 2 study of tibulizumab in an additional autoimmune indication by year-end 2026.

We’re incredibly grateful to our teams, patients, investigators, and partners who make this progress possible.

View the full announcement: https://t.co/rlmV12f2zo

[ZuraBio @ZuraBioLimited]

On World Scleroderma Day, we raise awareness of systemic sclerosis (#SSc), an autoimmune disease that can affect the skin and internal organs and place a significant burden on daily life. We recognize the strength of those living with SSc and the families and caregivers who support them.

Learn more about SSc: https://t.co/HsvBO0Yvjr

#WorldSclerodermaDay #AutoimmuneDisease #DiseaseAwareness #ZuraBio

[ZuraBio @ZuraBioLimited]

Tune in to the latest episode of The BioHub Podcast, hosted by Max Brennan, to hear Sandeep Kulkarni, CEO of Zura Bio, share his journey from investor to operator, what it takes to lead a biotech company, and why Zura’s multi-asset approach in autoimmune disease stands out.

🎙️ Catch the full discussion: https://t.co/iQsoFoPWRU

[ZuraBio @ZuraBioLimited]

Living with hidradenitis suppurativa (#HS) often means navigating chronic pain, inflammation, and lasting impacts on quality of life.

During #HSAwarenessWeek, we stand with the HS community to highlight the need for greater awareness, deeper understanding, and continued research. At Zura Bio, we are proud to support ongoing clinical efforts aimed at advancing science and improving outcomes for people living with HS.

#HidradenitisSuppurativa #AutoimmuneDisease #ZuraBio

[ZuraBio @ZuraBioLimited]

Autoimmune Awareness Month is about visibility, understanding, and keeping focus on people living with autoimmune disease.

At Zura Bio, their experiences and the unmet needs they face help shape how we approach our work and design our clinical programs, including our Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (#HS) and systemic sclerosis (#SSc).

#AutoimmuneAwarenessMonth #ZuraBio #TibuSHIELD #TibuSURE

[ZuraBio @ZuraBioLimited]

March is Autoimmune Awareness Month, a time to recognize the millions of people living with autoimmune diseases and the importance of awareness, earlier diagnosis, and better care.

At Zura Bio, our work is guided by those living with these diseases and the communities that support them. We are researching potential new medicines for serious autoimmune and inflammatory conditions, including ongoing Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (#HS) and systemic sclerosis (#SSc).

Learn more: https://t.co/U7gc3ch2lg

#AutoimmuneAwarenessMonth #ZuraBio #TibuSURE #TibuSHIELD

[ZuraBio @ZuraBioLimited]

Today, Zura Bio reported our financial results for 2025, along with recent corporate updates.

For more information, please read the full press release here: https://t.co/apZZkTewi5

$ZURA #FinancialResults

[ZuraBio @ZuraBioLimited]

To mark the recent closing of its $144 million public offering, @ZuraBioLimited was recognized on the @Nasdaq Tower in Times Square.

As we recognize #AutoimmuneAwarenessMonth, we thank the life sciences investors who participated and share our commitment to advancing meaningful innovation for patients with serious autoimmune and inflammatory diseases.

Thank you to Nasdaq for highlighting this milestone as we continue executing our mission.

#ZuraBio #NasdaqListed $ZURA #Immunology

Photo courtesy of Nasdaq, Inc.

[ZuraBio @ZuraBioLimited]

#TeamZura is onsite this week at the 9th Systemic Sclerosis World Congress in Athens, Greece as we present a study design poster for our global Phase 2 TibuSURE clinical trial evaluating tibulizumab in systemic sclerosis (#SSc).

Read the full press release here: https://t.co/ph0woYQbqV

[ZuraBio @ZuraBioLimited]

Momentum continues as #TeamZura heads to Miami for the Leerink Global Healthcare Conference and the Jefferies Biotech on the Beach Summit.

We look forward to discussing progress across our clinical programs and sharing perspective on key milestones ahead, including work evaluating tibulizumab, an investigational first- and only-in-class dual-pathway bispecific antibody targeting BAFF and IL-17, in clinical trials for systemic sclerosis (#SSc) and hidradenitis suppurativa (#HS).

Read the full press release: https://t.co/viM8YeNHBy

[ZuraBio @ZuraBioLimited]

Rare Disease Day is February 28.

Living with a rare disease often means navigating delayed diagnosis, limited treatment options, and daily uncertainty. For people affected by systemic sclerosis (#SSc), also known as scleroderma, the complexity of the disease highlights the critical role of caregivers and healthcare professionals.

On Rare Disease Day, Zura Bio stands with the rare disease community. We recognize patients, caregivers, and healthcare professionals, and support efforts to raise awareness and understanding.

Learn more: https://t.co/BiKb48dpHD

#RareDiseaseDay #RareDiseaseAwareness #ZuraBio

[ZuraBio @ZuraBioLimited]

We’re excited to welcome Mark Eisner, MD, MPH and Ajay Nirula, MD, PhD, to our Board of Directors.

Both have led innovative biologics from early development through global approval and commercialization, bringing decades of experience advancing therapies in autoimmune disease.

As we continue executing on our differentiated dual-pathway platform targeting IL-17 and BAFF, their insight will help shape what comes next.

Read more: https://t.co/Me0CfU1VVs

[ZuraBio @ZuraBioLimited]

Systemic sclerosis (#SSc), also known as scleroderma, is a rare, heterogeneous, and complex rheumatic autoimmune disease that can affect the skin, blood vessels, and internal organs and often has a significant impact on daily life.

At Zura, we focus on SSc because of its complexity and the unmet needs faced by patients and families. As Rare Disease Day (February 28) approaches, we continue our work through clinical research, including our ongoing Phase 2 TibuSURE trial evaluating tibulizumab, an investigational bispecific antibody targeting BAFF and IL-17, in SSc.

Learn more about our clinical research: https://t.co/U7gc3ch2lg

#RareDiseaseDay #RareDiseaseAwareness #SSc #Scleroderma #ZuraBio

[ZuraBio @ZuraBioLimited]

We’re heading to the @GuggenheimSec Emerging Outlook: Biotech Summit.

Our leadership team will discuss how we are advancing a focused strategy in rare and complex immune diseases, with continued execution across our clinical-stage programs.

Read the full press release: https://t.co/APkOgpX6BP

[ZuraBio @ZuraBioLimited]

We’re excited to welcome Sandeep Kulkarni, M.D., as Chief Executive Officer of Zura Bio.

Sandeep brings more than two decades of experience across biotechnology, medicine, and leadership and has been part of the Zura journey since its inception through his service on our Board of Directors. As we enter an important period for Zura with multiple upcoming clinical readouts, we’re thrilled to have his leadership guiding the next chapter of our growth.

Welcome, Sandeep—we’re excited for what’s ahead.

Read the full press release here: https://t.co/cUcYcGKY3R